HR+ Breast Cancer: 2022 Year in Review

Virginia Kaklamani, MD and Heather McArthur, MD discuss updates in HR+ breast cancer, with a focus on treatment options before and after progression, treatment selection, and emerging data.

EP. 1: Introduction to the HR+ Treatment Landscape

December 15th 2022

Virginia Kaklamani, MD and Heather McArthur, MD begin by discussing new data regarding the use of aromatase inhibitors and ovarian function suppression in women with HR+ early breast cancer.

EP. 2: Disparities in Clinical Trials of HR+ Breast Cancer

January 9th 2023

Dr Kaklamani and Dr McArthur review data concerning racial disparities within breast cancer treatment populations and speculate how these challenges might be overcome.

EP. 3: New Data and Clinical Factors Contributing to CDK4/6 Inhibitor Selection

January 9th 2023

Two breast cancer experts delve into key data from various CDK4/6 inhibitor studies, focusing on safety, efficacy, and how these agents might be implemented in the clinic.

EP. 4: Exploring Treatment Options After First Line CDK4/6 Inhibitor plus Endocrine Therapy

January 13th 2023

Insights concerning treatment selection beyond the first line in patients with HR+ metastatic breast cancer.

EP. 5: Additional Perspectives on Treatment Selection and Sequencing in Metastatic Breast Cancer

January 13th 2023

Dr Kaklamani and Dr McArthur share their experiences with CDK4/6 inhibitors and discuss how new data may change their approaches to sequencing treatments in the clinic.

EP. 6: Emerging Data on HER2-Low Breast Cancer and Clinical Implications

January 20th 2023

Discussion centered around new HER2-low data and treating patients with HER2-low breast cancer effectively.

EP. 7: Looking Forward: Breast Cancer Treatment in 2023 and Beyond

January 20th 2023

Virginia Kaklamani, MD and Heather McArthur, MD, MPH close by sharing exciting prospects in metastatic breast cancer treatment.